Five-Year Prostate-Specific Membrane Antigen Positron Emission Tomography-Based Outcomes of Spot-Scanning Proton Radiation Therapy for Localized Prostate Cancer: A Single Institution Experience.

ABSTRACT:

Purpose

We report 5-year oncologic outcomes of a prospective series of patients with prostate cancer treated with spot-scanning proton therapy (SSPT).

Methods and materials

A prospective registry identified patients with prostate cancer treated with SSPT between January 2016 and December 2018. Five-year overall survival, local control, biochemical failure, regional and distant failures, and adverse events (AEs) were assessed. Biochemical failure was defined as rise in prostate-specific antigen ≥ 2.0 ng/mL above nadir prostate-specific antigen. Baseline-adjusted toxicities were assigned using the Common Terminology Criteria for Adverse Events version 5.0.

Results

With a median follow-up of 4.4 years, 284 patients with prostate cancer were treated with SSPT. Median tota

SUBMITTER: Sperduto W 

PROVIDER: S-EPMC11602970 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature